Catalog No.
DVV02822
Expression system
Mammalian Cells
Species reactivity
Human respiratory syncytial virus A (strain A2)
Host species
Human
Isotype
IgG1
Clonality
Monoclonal
Applications
Research Grade Biosimilar
Target
F, Fusion glycoprotein F0, Fusion glycoprotein F2, p27, Intervening segment, Pep27, Peptide 27, Fusion glycoprotein F1
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P03420
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
ADI-14442, ADI14442, ADI 14442
Clone ID
ADI-14442
Note
For research use only. Not suitable for clinical or therapeutic use.
The respiratory syncytial virus fusion protein-specific B cell receptor repertoire reshaped by post-fusion subunit vaccination., PMID:33131932
Prevention of Respiratory Syncytial Virus Infection in Healthy Adults by a Single Immunization of Ad26.RSV.preF in a Human Challenge Study., PMID:33400792
Vaccination with prefusion-stabilized respiratory syncytial virus fusion protein induces genetically and antigenically diverse antibody responses., PMID:33823129
Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial., PMID:33864736
In silico virtual screening of lead compounds for major antigenic sites in respiratory syncytial virus fusion protein., PMID:33969268
Level of maternal respiratory syncytial virus (RSV) F antibodies in hospitalized children and correlates of protection., PMID:34118428
Respiratory Syncytial Virus (RSV)-Specific Antibodies in Pregnant Women and Subsequent Risk of RSV Hospitalization in Young Infants., PMID:34129040
COVID-19, Influenza and RSV: Surveillance-informed prevention and treatment - Meeting report from an isirv-WHO virtual conference., PMID:34933044
Evolution of protection after maternal immunization for respiratory syncytial virus in cotton rats., PMID:34941963
Elicitation of pneumovirus-specific B cell responses by a prefusion-stabilized respiratory syncytial virus F subunit vaccine., PMID:35731888
Immunogenicity and protective efficacy of RSV G central conserved domain vaccine with a prefusion nanoparticle., PMID:35773301
Divergent age-related humoral correlates of protection against respiratory syncytial virus infection in older and young adults: a pilot, controlled, human infection challenge model., PMID:36098319
Split-Dose Administration Enhances Immune Responses Elicited by a mRNA/Lipid Nanoparticle Vaccine Expressing Respiratory Syncytial Virus F Protein., PMID:36251490
An Optimized FI-RSV Vaccine Effectively Protects Cotton Rats and BALB/c Mice without Causing Enhanced Respiratory Disease., PMID:36298640
RSV pre-fusion F protein enhances the G protein antibody and anti-infectious responses., PMID:36535957
A prefusion-stabilized RSV F subunit vaccine elicits B cell responses with greater breadth and potency than a postfusion F vaccine., PMID:36542692
Virus-like particles containing a prefusion-stabilized F protein induce a balanced immune response and confer protection against respiratory syncytial virus infection in mice., PMID:36578490
The Respiratory Syncytial Virus (RSV) G Protein Enhances the Immune Responses to the RSV F Protein in an Enveloped Virus-Like Particle Vaccine Candidate., PMID:36602367
A human antibody potently neutralizes RSV by targeting the conserved hydrophobic region of prefusion F., PMID:36853487
Virus-like Particle Vaccine Expressing the Respiratory Syncytial Virus Pre-Fusion and G Proteins Confers Protection against RSV Challenge Infection., PMID:36986643
Development of a Kinetic ELISA and Reactive B Cell Frequency Assay to Detect Respiratory Syncytial Virus Pre-Fusion F Protein-Specific Immune Responses in Infants., PMID:37029694
The Efficiency of p27 Cleavage during In Vitro Respiratory Syncytial Virus (RSV) Infection Is Cell Line and RSV Subtype Dependent., PMID:37133390
Gamma Irradiation-Inactivated Respiratory Syncytial Virus Vaccine Provides Protection but Exacerbates Pulmonary Inflammation by Switching from Prefusion to Postfusion F Protein., PMID:37272801
Development of Respiratory Syncytial Virus Vaccine Candidates for the Elderly., PMID:37376605
Virus-Like Particles Assembled Using Respiratory Syncytial Virus Matrix Protein Elicit Protective Immunity in Mice., PMID:37719656
Structure-based design of a single-chain triple-disulfide-stabilized fusion-glycoprotein trimer that elicits high-titer neutralizing responses against human metapneumovirus., PMID:37738240
Assessing the protection elicited by virus-like particles expressing the RSV pre-fusion F and tandem repeated G proteins against RSV rA2 line19F infection in mice., PMID:38178222
[Prevention of respiratory syncytial virus infection in infants. What has been done and where are we today?]., PMID:38329302
Mutations in the F protein of the live-attenuated respiratory syncytial virus vaccine candidate ΔNS2/Δ1313/I1314L increase the stability of infectivity and content of prefusion F protein., PMID:38593167
Intranasal respiratory syncytial virus vaccine attenuated by codon-pair deoptimization of seven open reading frames is genetically stable and elicits mucosal and systemic immunity and protection against challenge virus replication in hamsters., PMID:38739647
Exacerbated lung inflammation in offspring with high maternal antibody levels following secondary RSV exposure., PMID:38745662
Antibody responses to respiratory syncytial virus: a population-based cross-sectional serological study in Southern China, 2021., PMID:38852851
Development and Validation of an Enzyme-Linked Immunosorbent Assay-Based Protocol for Evaluation of Respiratory Syncytial Virus Vaccines., PMID:38932244
Antibody levels against respiratory syncytial virus fusion protein conformations and lack of association with life-threatening infection in previously healthy infants., PMID:39003106
Confronting the challenge: a regional perspective by the Latin American pediatric infectious diseases society (SLIPE) expert group on respiratory syncytial virus-tackling the burden of disease and implementing preventive solutions., PMID:39144471
Mutating a flexible region of the RSV F protein can stabilize the prefusion conformation., PMID:39325881
RSV Neutralizing Antibodies Following Nirsevimab and Palivizumab Dosing., PMID:39350745
Induction of neutralizing antibody responses by AAV5-based vaccine for respiratory syncytial virus in mice., PMID:39469716
Novel intercellular spread mode of respiratory syncytial virus contributes to neutralization escape., PMID:39489301
Serum and mucosal antibody-mediated protection and identification of asymptomatic respiratory syncytial virus infection in community-dwelling older adults in Europe., PMID:39493753
Safety and immunogenicity of the Ad26/protein preF RSV vaccine in adults aged 18 to 59 years with and without at-risk comorbidities for severe respiratory syncytial virus disease: A phase 3, randomized, controlled, immunobridging trial., PMID:39536455
DS2 designer pre-fusion F vaccine induces strong and protective antibody response against RSV infection., PMID:39741146
Protective or limited? Maternal antibodies and RSV-associated lower respiratory tract infection in hospitalized infants aged 28-90 days., PMID:39845974
Robust and Long-Lasting Immunity and Protection in Mice Induced by Lipopolyplex-Delivered mRNA Vaccines Expressing the Prefusion Protein of Respiratory Syncytial Virus., PMID:39852872
A truncated pre-F protein mRNA vaccine elicits an enhanced immune response and protection against respiratory syncytial virus., PMID:39910047
Recovery of Antibody Immunity After a Resurgence of Respiratory Syncytial Virus Infections., PMID:40099894
Strength and durability of RSV pre-fusion F IgG following infection and exposure in a household cohort, 2014-2022., PMID:40176487
Single-Dose Intranasal Immunization with ChAd68-Vectored Prefusion F Vaccines Confers Sustained Protection Against Respiratory Syncytial Virus in Murine Models., PMID:40432136
Hydrophobic residue substitutions enhance the stability and in vivo immunogenicity of respiratory syncytial virus fusion protein., PMID:40434102
For research use only. Not for human or drug use.
